Updated by Faith Barbara N Ruhinda at 1205 EAT on Friday 20 November 2026

Demand for lenacapavir, a long-acting HIV prevention injection administered twice a year, has exceeded available supplies in Uganda, Kenya and Malawi, prompting health officials and advocates to caution against generating demand that health systems may struggle to meet.
The concerns were raised during a regional webinar on expanding access to lenacapavir for pre-exposure prophylaxis (PrEP) in the three countries.
Warren Mitchell, executive director of AVAC, said the countries had reported similar experiences, highlighting the need to develop communication materials in consultation with communities, engage trusted local voices and integrate the injection into broader HIV prevention programmes.
Uganda reports more new users than expected
Dr Peter Mudiope, the Ministry of Health’s HIV prevention coordinator, said some people who had previously declined other forms of PrEP were now expressing interest in the injection.
“Our initial assumption was to switch people from oral PrEP to LEN, those who were willing. But we realised that some people are not willing to leave oral PrEP. So we have to respect that in the demand generation… We are seeing that there are many more new users of PrEP in the country,” he said.


He said the initial rollout highlighted the need to balance demand generation with the availability of supplies.
“When we launched PrEP on April 17 this year, we had only 20 doses for the site, and they got finished. Yet we had to reserve the doses for the next six months. We had to call the hospital to come to the launch place. That’s when we realised that we had to promote it as an option…” Mudiope said.
Uganda currently has 103 health facilities offering lenacapavir and expects additional doses in December, according to Mudiope.
He said the new supplies would initially be distributed to regions and health facilities with high numbers of people using oral PrEP.
The Ministry of Health had planned to expand the number of facilities offering lenacapavir from 103 to 300 by December 2026.
Meanwhile, the ministry is urging people to continue using other HIV prevention options as supplies of lenacapavir increase. These include daily oral PrEP, the dapivirine vaginal ring and injectable cabotegravir, which is administered every two months.
Mudiope said Uganda was also considering how to position long-acting HIV prevention products, including whether to continue offering cabotegravir alongside lenacapavir or reserve it for specific circumstances.
Building trust in communities
Kenneth Mwehonge, executive director of HEPS Uganda, said introducing lenacapavir required more than awareness campaigns, calling for investment in community structures to provide accurate information, counter stigma and misinformation, and link interested individuals to health facilities.
HEPS Uganda has worked with communities, local governments and health facilities to train 246 community resource persons from 115 PrEP implementation sites. The organisation also trained 27 national trainers, including Ministry of Health officials.
Mwehonge said the approach focused on equipping people who were already trusted within their communities rather than creating parallel structures.
“Communities believe in their peers, and those are the ones, once equipped with the right information, who support in addressing stigma and misinformation. So it has to be a trusted voice within the community,” he said.
The project also supported a revision of Uganda’s PrEP communication strategy to incorporate lenacapavir alongside other HIV prevention options.
The Ministry of Health’s communication department reviewed the materials before they were approved by the Uganda AIDS Commission.
Mwehonge said a key lesson from the initiative was the need to integrate community mobilisation into existing health structures to ensure the efforts are sustained beyond short-term donor-funded projects.


Patricia Jeckonia, programme manager for policy, advocacy and HIV prevention at Kenya’s LVCT Health, said the country’s experience showed how supply shortages could erode community confidence when people are encouraged to seek a prevention product that is not consistently available.
Kenya deliberately designed its campaign around a range of HIV prevention options rather than focusing exclusively on lenacapavir. The approach followed concerns that the introduction of newer products was affecting uptake of oral PrEP and leaving some people unaware of alternative prevention methods.
Communication messages were developed in consultation with adolescent girls and young women, pregnant and breastfeeding women, adolescent boys and young men, as well as other priority groups. The programme also engaged social media influencers trusted by these communities to help spread information.
Despite these efforts, supplies were quickly depleted, with some people arriving at health facilities only to find the injection unavailable.
“Every time you had LEN in a facility, it would take two to three days, and it’s over. So that continued. But our demand generation was also very targeted to the counties that were prioritised and around facilities that were providing PrEP choice,” Jeckonia said.
She said Kenya’s experience highlighted the importance of promptly communicating supply interruptions and equipping health workers with information to guide clients on alternative prevention options.
“Even when there is not yet enough supply, it is very important to empower communities with the right information so that they are aware of what’s available. We give all of the information, but inform them that their supply is not yet enough for now. It’s being rolled out. However, we are also promoting the other options,” she said.
Jeckonia said demand generation should be incorporated into product rollout plans from the outset, rather than treated as a secondary activity.
“Demand generation should not be an afterthought. It should be at the very beginning when we are thinking about availability of the product. We should be thinking about how people will know and invest in it,” she said.
Malawi adopts phased approach
Simon Sikwese, executive director of Pokachere in Malawi, said the country distributed communication materials in phases to avoid generating demand in districts where lenacapavir was not yet available.
He said awareness campaigns needed to be aligned with the capacity of health facilities to provide the injection.
“Ensure that you don’t create demand that you cannot meet. You must look at, for example, in the case of Lenacapavir, how much Lenacapavir you are receiving and how much demand you should create to make sure that you are not exciting people and then, in the end, they don’t access the Lenacapavir,” Sikwese said.
-Observer
Invest or Donate towards HICGI New Agency Global Media Establishment – Watch video here
Email: editorial@hicginewsagency.com TalkBusiness@hicginewsagency.com WhatsApp +256713137566
Follow us on all social media, type “HICGI News Agency” .
